ArticleBMC gastroenterology2025
Upadacitinib induction therapy in Crohn' s disease: a retrospective real-world study in biologic-refractory patients.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn's Disease.Diseases (Basel, Switzerland) · 2026Article
- A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease: Effectiveness, Persistence, and Safety.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
aimsUpadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, has demonstrated efficacy in clinical trials for Crohn's disease (CD) but real-world evidence remains limited. This study aimed to evaluate the effectiveness and safety of upadacitinib as induction therapy in a Chinese cohort with active CD.
methodsWe conducted a retrospective, single-center cohort study of CD patients who received upadacitinib at Union Hospital (Wuhan, China) between June 2023 and February 2025. Clinical and endoscopic outcomes and safety events were systematically assessed. Multivariate analyses were performed to identify predictors of therapeutic response.
results94 patients met inclusion criteria, endoscopic response and remission were achieved in 50.00% and 38.89%, while mucosal healing occurred in 27.78% by week 12. 53.25% achieved clinical response and 42.86% achieved clinical remission. Biomarker normalization was observed in 62.71% (CRP), 70.91% (ESR), and 29.63% (fecal calprotectin). Adverse events were recorded in 34.0% of patients, with lymphopenia being the most frequent. Lower baseline CDAI and SES-CD scores were associated with higher remission rates.
conclusionThis real-world study demonstrates that upadacitinib is effective and generally well tolerated in biologic-experienced Chinese patients with active CD. Our findings support the clinical utility of JAK1 inhibition in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.